F
orty years ago, the number of patients diagnosed as affected by long QT syndrome (LQTS) was very small (1) , and even the best cardiology centers had seen only a handful of them.
Almost nothing was known about the natural history and the response to therapy. As evidence, we may recall that Dirk Durrer (a pioneer of cardiac electrophysiology) wrote to Conor Ward (of the Romano-Ward syndrome) "I am pessimistic about the possibility to control the syndrome in any way,"
and that in the early 1970s, one of the initially favored therapies was digitalis (1) . Therefore, the only way to understand these aspects, critical for any "newly discovered" disease, was to establish an International Registry (2-4).
Besides paving the way to the genetic discoveries (4), the fruits of the LQTS registry were truly significant. They showed, for instance, that the risk for major cardiac events (syncope, cardiac arrest, and sudden death) is higher when the QT interval is longer, when a syncope has already occurred, and among women especially after puberty, and that ß-blocker therapy is very effective (5, 6) . The registry was the only way to make progress at a time when the diagnosed cases were so few, but it contained the germ of a problem. Moss in the United States and Schwartz in Europe, but covering also Asia and Africa, were sending out forms to the many physicians who had either published 1 or a few cases or had inquired for advice; the completed forms were returned to Rochester, were the source for analysis, and were regularly updated. Over the years, the system was significantly refined, but the critical limitation (i.e., the fact that the specific drugs used and their dosages relevant to the contents of this paper to disclose. We stand by what we wrote in 2003, and at our center in Milan, it is our policy to always consider these possibilities. The confirmation by Rohatgi et al. 
